ClinicalTrials.gg
CompletedNCT04063163Updated Dec 9, 2025Results posted

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

A Phase 3 interventional study of HLX10 and carboplatin and etoposide in Extensive Stage Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
585
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer.

Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:

Arm A (HLX10 arm): HLX10 + chemotherapy (Carboplatin-Etoposide) ; Arm B (placebo arm): Placebo + chemotherapy (Carboplatin-Etoposide); The three stratification factors for randomization include: PD-L1 expression level (negative, positive, not available), Brain metastasis (yes versus no), Age (≥ 65 years versus \< 65 years)

Read the detailed description

After screening, subjects meeting the inclusion criteria and none of the exclusion criteria will be enrolled. Included subjects will be treated with HLX10 or placebo in combination with chemotherapy once every 3 weeks, until disease progression, death, intolerable toxicity, withdrawal of informed consent, or occurrence of other reasons specified in the protocol (whichever occurs first).

02

Conditions studied

  • Extensive Stage Small Cell Lung Cancer

Keywords

  • Extensive Stage
  • Small Cell Lung Cancer
  • Anti-PD-1 Monoclonal Antibody
03

In context

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

This study's enrollment of 585 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.

Browse Small Cell Lung Carcinoma studies →

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).
  • No prior systemic therapy for ES-SCLC
  • Major organs are functioning well
  • Participant must keep

Exclusion criteria

Exclusion Criteria:

  • or cytologically confirmed mixed SCLC.
  • Known history of severe allergy to any monoclonal antibody.
  • Known to carboplatin or etoposide.
  • Pregnant or breastfeeding females.
  • Patients with a known history of psychotropic drug abuse or drug addiction.
  • Patients who have other factors that could lead to the early termination of this study based on the investigator's judgment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
585 participants (actual)

Study arms

  • Experimental
    A

    HLX 10+chemotherapy (Carboplatin-Etoposide)

    Drug: HLX10 · Drug: carboplatin and etoposide

  • Placebo comparator
    B

    Placebo+chemotherapy (Carboplatin-Etoposide)

    Drug: carboplatin and etoposide · Drug: placebo

Interventions

  • DrugHLX10

    HLX10 is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc.

  • Drugcarboplatin and etoposide

    Drug pages: Carboplatin · Etoposide

    chemotherapeutics

  • Drugplacebo

    placebo

06

What researchers measure

Primary outcomes

  1. OS

    Overall survival (OS)

    Time frame: The period from randomization through death regardless of causality (up to approximately 56 months)

Secondary outcomes

  1. Progression Free Survival (PFS) Assessed by IRRC According to RECIST 1.1

    PFS is defined as a period from randomization initiation to the first documentation of PD or death regardless of causality (whichever occurs first).

    Time frame: From randomization initiation to the first documentation of PD or death regardless of causality, whichever occurs first (up to approximately 56 months).

  2. Objective Response Rate

    The ORR is defined as the proportion of subjects with a best overall response of CR or PR, according to RECIST 1.1. The best overall response will be defined as the best response across all time points in the order of CR, PR, SD, PD, and not NE.

    Time frame: From baseline until PR or CR, whichever occurs first (up to approximately 56 months)

  3. Duration of Response

    DOR is defined as a period from the first documentation of response (CR or PR) through the first documentation of PD or death (whichever occurs first).

    Time frame: From the first documentation of response (CR or PR) through the first documentation of PD or death, whichever occurs first (up to approximately 56 months).

07

Results

Posted Dec 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneGroup AGroup B
Started389196
Completed7712
Not completed312184
Withdrew: Death281166
Withdrew: Lost to follow-up128
Withdrew: Withdrawal by subject1910

Outcome measures

PrimaryOS

Overall survival (OS)

Time frame:
The period from randomization through death regardless of causality (up to approximately 56 months)
Reported as:
Median · month
OS
monthA GroupsB Groups
OS15.77 (13.897 to 17.413)11.10 (9.955 to 12.353)
Statistical analysis
  • A Groups vs B Groups · Log Rank · p = <0.001 · Hazard ratio (hr): 0.62 · 95% CI 0.496 to 0.763
SecondaryProgression Free Survival (PFS) Assessed by IRRC According to RECIST 1.1

PFS is defined as a period from randomization initiation to the first documentation of PD or death regardless of causality (whichever occurs first).

Time frame:
From randomization initiation to the first documentation of PD or death regardless of causality, whichever occurs first (up to approximately 56 months).
Reported as:
Median · month
Progression Free Survival (PFS) Assessed by IRRC According to RECIST 1.1
monthA GroupsB Groups
Progression Free Survival (PFS) Assessed by IRRC According to RECIST 1.15.82 (5.552 to 6.932)4.34 (4.205 to 4.435)
Statistical analysis
  • A Groups vs B Groups · Log Rank · p = 0.001 · Hazard ratio (hr): 0.47 · 95% CI 0.381 to 0.576
SecondaryObjective Response Rate

The ORR is defined as the proportion of subjects with a best overall response of CR or PR, according to RECIST 1.1. The best overall response will be defined as the best response across all time points in the order of CR, PR, SD, PD, and not NE.

Time frame:
From baseline until PR or CR, whichever occurs first (up to approximately 56 months)
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsA GroupsB Groups
Objective Response Rate268115
SecondaryDuration of Response

DOR is defined as a period from the first documentation of response (CR or PR) through the first documentation of PD or death (whichever occurs first).

Time frame:
From the first documentation of response (CR or PR) through the first documentation of PD or death, whichever occurs first (up to approximately 56 months).
Reported as:
Median · month
Duration of Response
monthA GroupsB Groups
Duration of Response6.80 (5.520 to 8.345)4.17 (3.055 to 4.205)

Adverse events

Collected over From ICF until 90 days after the last study treatment (up to approximately 56 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A224/389 (57.6%)146/389 (37.5%)367/389 (94.3%)
Group B140/196 (71.4%)71/196 (36.2%)187/196 (95.4%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventGroup AGroup B
Disease progressionGeneral disorders29/38919/196
Neutrophil count decreasedInvestigations17/38918/196
platelet count decreasedBlood and lymphatic system disorders25/38915/196
Neutrophil count decreasedInvestigations17/38911/196
PneumoniaInfections and infestations14/3897/196
DeathGastrointestinal disorders11/3897/196
NeutropeniaBlood and lymphatic system disorders11/3894/196
ThrombocytopeniaBlood and lymphatic system disorders11/3894/196
AnaemiaBlood and lymphatic system disorders6/3895/196
LeukopeniaBlood and lymphatic system disorders9/3893/196
Most frequent other events
Showing 10 of 62
Most frequent other events
EventGroup AGroup B
AnaemiaBlood and lymphatic system disorders279/389139/196
AlopeciaSkin and subcutaneous tissue disorders211/389111/196
Neutrophil count decreasedInvestigations217/38996/196
White blood cell count decreasedInvestigations205/38998/196
NauseaGastrointestinal disorders140/38986/196
Platelet count decreasedInvestigations157/38985/196
NeutropeniaBlood and lymphatic system disorders115/38959/196
ConstipationGastrointestinal disorders94/38958/196
VomitingGastrointestinal disorders78/38958/196
Decreased appetiteMetabolism and nutrition disorders109/38956/196

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Mean63 (28 to 76)62 (31 to 83)62 (28 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female72164236
Male31732349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group AGroup BTotal
Asian262139401
Non-Asian12757184
Smoking history
Smoking history(Participants)Group AGroup BTotal
Never smoker8135116
Current smoker10248150
Former smoker206113319
08

Study locations

5 sites
  • Institute for Personalized Medicine
    Tbilisi, Georgia
  • Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi
    Lodz, Poland
  • Arkhangelsk Clinical Oncology Dispensary
    Arkhangelsk, Russia
  • Medipol Mega Hospital
    Istanbul, Turkey (Türkiye)
  • Komunalnyi zaklad Miska bahato
    Dnipropetrovsk, Ukraine
09

References and documents

Publications

  • Liu J, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Shi J, Pan Z, Shi J, Wang X, Bai Y, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Yu H, Li J, Yang X, Wang Q, Zhu J; ASTRUM-005 Study Group. First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 Jun 4:e261645. doi: 10.1001/jamaoncol.2026.1645. Online ahead of print. PubMed 42240984 ↗
  • Wang K, Shen Y, Hu C, Xu F, Wang Q, Gao Y, Zhou L. Population Pharmacokinetics and Exposure-Response Analysis of Serplulimab in Small Cell Lung Cancer Patients. Clin Transl Sci. 2025 Sep;18(9):e70322. doi: 10.1111/cts.70322. PubMed 40932107 ↗
  • Zhu Y, Liu K, Qin Q, Zhu H. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Front Immunol. 2023 Jan 4;13:1044678. doi: 10.3389/fimmu.2022.1044678. eCollection 2022. PubMed 36685541 ↗
  • Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Kang W, Wang Q, Zhu J; ASTRUM-005 Study Group. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA. 2022 Sep 27;328(12):1223-1232. doi: 10.1001/jama.2022.16464. PubMed 36166026 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in May 2024, 55 months.

Results were first posted in Dec 2025, 1 year 7 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 55 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2019
First posted
Aug 21, 2019
StartActual
Sep 12, 2019
Primary completionActual
May 7, 2024
CompletionActual
May 7, 2024
Results first posted
Dec 9, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04063163
Responsible party
Sponsor
First posted
Aug 21, 2019
Start date
Sep 12, 2019
Primary completion
May 7, 2024
Completion
May 7, 2024
Results posted
Dec 9, 2025
Last update
Dec 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion